Last reviewed · How we verify
Actrapid (human insulin)
Actrapid (human insulin) is a Insulin, rapid-acting Small molecule drug developed by University of Aarhus. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
Actrapid is human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.
Actrapid (human insulin) is a protein-based insulin receptor agonist used to treat conditions such as Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and Hyperglycemia. It is classified as an agonist and works by activating the insulin receptor.
At a glance
| Generic name | Actrapid (human insulin) |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | Insulin, rapid-acting |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Actrapid is a rapid-acting human insulin formulation that mimics the body's natural insulin response to meals. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into these tissues and promoting glycogen synthesis while inhibiting gluconeogenesis. This results in rapid reduction of postprandial and fasting blood glucose levels in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Text Message for Adolescents With Poorly Controlled Type 1 Diabetes (NA)
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD
- Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise (NA)
- Critical Food Ingredients on Immunocompetence to Prevent the Risk and Development of Obesity/Metabolic Syndrome (NA)
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actrapid (human insulin) CI brief — competitive landscape report
- Actrapid (human insulin) updates RSS · CI watch RSS
- University of Aarhus portfolio CI
Frequently asked questions about Actrapid (human insulin)
What is Actrapid (human insulin)?
How does Actrapid (human insulin) work?
What is Actrapid (human insulin) used for?
Who makes Actrapid (human insulin)?
What drug class is Actrapid (human insulin) in?
What development phase is Actrapid (human insulin) in?
What are the side effects of Actrapid (human insulin)?
What does Actrapid (human insulin) target?
Related
- Drug class: All Insulin, rapid-acting drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: University of Aarhus — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing